Where Rallybio Stands With Analysts
Portfolio Pulse from Benzinga Insights
Rallybio (NASDAQ:RLYB) has received positive analyst ratings in the last quarter, with 7 bullish and 4 somewhat bullish ratings. The average 12-month price target for the stock is $17.14, representing a 20.28% decrease from the previous average price target of $21.50.
September 05, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Rallybio has received positive analyst ratings, but the average 12-month price target has decreased by 20.28%.
While the analyst ratings for Rallybio are positive, the decrease in the average 12-month price target could indicate a potential decrease in the stock's value. However, the impact of analyst ratings on stock prices can vary and is not always immediate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100